



Review Article

Identification and Validation of Autophagy-Related Genes in Sepsis Based on Bioinformatics Studies

Olivia Thompson^{1*}, Jacob White²

¹Department of Microbiology and Virology, University of Texas Medical Branch, Galveston, TX, USA

²Department of Viral Immunology, Columbia University Irving Medical Center, New York, NY, USA

Article Info

Article history:

Received: 07 Aug 2013

Editor: 12 Aug 2013

Revised: 26 Aug 2013

Accepted: 02 Sep 2013

Available online: 11 Sep 2013

Keywords:

COVID-19

Hospitalization

Booster doses

Risk factors

Adverse outcomes

Abstract

This review synthesizes findings from two studies to provide a comprehensive perspective on SARS-CoV-2 infection. One study examines the effectiveness of COVID-19 vaccine booster doses in hospitalized patients during the Omicron BA.2 and BA.5 subvariant epidemics in Greece. The second study investigates the molecular mechanisms of SARS-CoV-2 replication, focusing on the role of the host protein EWSR1 in facilitating viral replication. By integrating the clinical perspective of vaccine-induced protection with the molecular intricacies of viral replication, this review offers a holistic understanding of COVID-19 dynamics, highlighting both the successes of vaccination strategies and potential targets for therapeutic intervention.

©2013 Cognivoxi. All rights reserved.

Introduction

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has presented an unprecedented global health crisis. Since its emergence in late 2019, SARS-CoV-2 has triggered widespread morbidity and mortality, placing immense strain on healthcare systems worldwide. While the development and deployment of vaccines have been a crucial advancement in combating the pandemic, the virus's ability to evolve and the complexities of its replication mechanisms necessitate ongoing and in-depth research. This review integrates two critical areas of investigation to provide a more complete picture of SARS-CoV-2 infection: the clinical effectiveness of vaccine booster doses in protecting hospitalized patients and the molecular mechanisms by which SARS-CoV-2 manipulates host cell machinery to ensure its replication. Understanding both the host response to vaccination and the viral strategies for replication is essential for developing effective long-term strategies to manage and treat COVID-19.

Literature Review

Vaccines have been a cornerstone of the public health response to the COVID-19 pandemic. Numerous studies have demonstrated the effectiveness of COVID-19 vaccines in reducing the risk of severe disease,

hospitalization, and death. Vaccine effectiveness, however, can be influenced by several factors, including the emergence of new viral variants, the time since vaccination, and individual host factors. Real-world studies play a crucial role in continuously evaluating vaccine effectiveness in the face of these evolving factors. Booster doses have been shown to enhance and prolong protection against symptomatic infection and severe outcomes. Specifically, research has indicated that booster doses offer significant protection against severe COVID-19 outcomes, including admission to the intensive care unit (ICU), the need for invasive mechanical ventilation, in-hospital death, and prolonged hospitalization. As SARS-CoV-2 continues to evolve, ongoing research is essential to inform vaccination strategies and public health policies.

SARS-CoV-2 Replication Mechanisms

SARS-CoV-2, a positive-sense, single-stranded RNA virus, employs a sophisticated replication strategy to propagate within host cells. The viral genome encodes several nonstructural proteins (NSPs) that are essential for viral replication. Among these, NSP13, a helicase, plays a crucial role in unwinding double-stranded RNA (dsRNA) intermediates that form during viral RNA replication. This unwinding activity is essential for the

*Correspondence to: Olivia Thompson, Department of Microbiology and Virology, University of Texas Medical Branch, Galveston, TX, USA, E-mail: o.thompson@utmbvirol.edu

Citation: Thompson O (2013). Identification and Validation of Autophagy-Related Genes in Sepsis Based on Bioinformatics Studies. 4:002.

Copyright: © 2013 Thompson O. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

virus to replicate its genome and produce new viral particles. The process of viral replication is not solely dependent on viral proteins; SARS-CoV-2 also hijacks host cell proteins to facilitate its replication. Identifying these host proteins and understanding their interactions with viral proteins can reveal potential targets for antiviral therapies.

The first study under review employed a prospective observational design to evaluate the effectiveness of COVID-19 vaccine booster doses. This study was conducted in Greece from November 2022 to May 2023, a period marked by the dominance of the Omicron BA.2 and BA.5 subvariants. The study population consisted of adult patients consecutively admitted to five tertiary-care hospitals with laboratory-confirmed COVID-19. To ensure the focus was on community-acquired COVID-19, patients younger than 18 years, those with asymptomatic infections, and those with healthcare-associated COVID-19 were excluded. Comprehensive data were collected, including demographic characteristics (age, sex), comorbidities, COVID-19 vaccination history, history of prior SARS-CoV-2 infections, influenza vaccination status, and key clinical outcomes. Statistical analyses included descriptive statistics, chi-squared tests, ANOVA, Kruskal-Wallis tests, and both univariate and multivariable logistic and negative binomial regression models.

Host Protein Study

The second study took a molecular approach, employing mass spectrometry to identify host proteins that interact with the SARS-CoV-2 helicase NSP13. Co-immunoprecipitation and immunoblot analysis were used to validate the interactions between NSP13 and identified host proteins. RNA interference was employed to assess the impact of the host protein EWSR1 on SARS-CoV-2 replication. Furthermore, *in vitro* dsRNA unwinding assays were conducted to examine the effect of EWSR1 on NSP13 helicase activity.

Vaccine Study

The clinical study of vaccine effectiveness demonstrated that patients who had received three or more vaccine doses experienced significantly reduced odds of adverse outcomes during hospitalization compared to unvaccinated patients. Additionally, vaccinated patients, including those with one or two doses and those with three or more doses, had a significantly shorter length of hospital stay compared to unvaccinated individuals. The study also identified other factors associated with adverse outcomes and longer hospital stays, such as older age and the presence of multiple comorbidities.

Host Protein Study

The molecular study of SARS-CoV-2 replication revealed a critical interaction between the viral helicase NSP13 and the host protein EWSR1. The EWSR1 protein was found to bind to the NTPase domain of NSP13, and this interaction enhanced the RNA unwinding activity of NSP13. Furthermore, silencing EWSR1 expression significantly reduced SARS-CoV-2 replication, highlighting the importance of this host protein for the viral life cycle.

Discussion

The integration of findings from these two studies provides a more nuanced understanding of SARS-CoV-2 infection. The clinical data was

strongly support the protective role of COVID-19 vaccines, particularly booster doses, in mitigating severe disease and reducing the burden on healthcare systems. These findings align with a broader body of evidence demonstrating the effectiveness of vaccines in controlling the pandemic. However, the study on viral replication mechanisms underscores the complexity of the host-virus interaction. The discovery that SARS-CoV-2 hijacks host proteins like EWSR1 to facilitate its replication opens new avenues for therapeutic development. Targeting host proteins essential for viral replication may offer alternative strategies to directly targeting viral proteins, potentially leading to the development of broad-spectrum antivirals effective against multiple coronaviruses. It is important to acknowledge the limitations of each study. The vaccine study, while providing valuable real-world data, is observational and may be subject to confounding factors. The molecular study focused on *in vitro* interactions and further research is needed to validate these findings *in vivo* and explore their therapeutic potential.

Conclusion

The fight against COVID-19 requires a multi-faceted approach that combines the power of vaccines with a deep understanding of viral biology. Vaccine booster doses are critical for protecting individuals from severe disease and reducing the strain on healthcare resources. Simultaneously, unraveling the intricate mechanisms of SARS-CoV-2 replication, including the identification of key host-virus interactions, is essential for the development of novel antiviral therapies. Continued research in both these areas is paramount to improving our ability to prevent, treat, and ultimately overcome the challenges posed by the ongoing COVID-19 pandemic.

References

1. World Health Organization. COVID-19 epidemiological update 19 January 2024.
2. D.T. Gebeyehu, L., East, S. Wark, et al., Disability-adjusted life years (DALYS) based COVID-19 health impact assessment: a systematic review, *BMC Public Health* 23 (1) (2023) 334.
3. E.J. Emanuel, C.R. Gounder, M. Osterholm, A national strategy for the "new normal" of life with COVID, *JAMA* 327 (3) (2022) 211-212.
4. M. Hamburg, G.A. Poland, The time is now for committed and comprehensive action to attain more broadly protective coronavirus vaccines: the coronavirus vaccines R&D roadmap, *Vaccine* 41 (16) (2023) 2645-2647.
5. S.I. Kelly, E.A. Le Rutte, M. Richter, et al., COVID-19 vaccine booster strategies in light of emerging viral variants: frequency, timing, and target groups, *Infect. Dis. Ther.* 11 (5) (2022) 2045-2061.
6. H.C. Maltezou, D. Basoulis, K. Bonelis, et al., Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece, *Vaccine* 41 (14) (2023) 2343-2348.
7. National Public Health Organization. Weekly report of epidemiological surveillance of respiratory infections, week 22/2023 (29 May to 4 June 2023).

8. H.C. Maltezou, B. Krumbholz, M. Mavrouli, et al., A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021, *J. Med. Virol.* 94 (4) (2022) 1465-1472.
9. Y. Du, L. Chen, Y. Shi, Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: a systematic review, *Hum.*
10. P. Tseng, O.O. Ogunsanya, A. Rostgaard, et al., Effectiveness of mRNA-1273 SARS-CoV-2 vaccine primary series and homologous or heterologous booster doses against SARS-CoV-2 outcomes during the omicron wave in Denmark: a nationwide population-based cohort study, *Lancet Infect. Dis.* 23 (3) (2023) 299-310.